Growth Metrics

Supernus Pharmaceuticals (SUPN) Non Operating Income: 2011-2025

Historic Non Operating Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $2.3 million.

  • Supernus Pharmaceuticals' Non Operating Income fell 44.44% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 22.66%. This contributed to the annual value of $16.2 million for FY2024, which is 55.02% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Non Operating Income of $2.3 million as of Q3 2025, which was down 49.71% from $4.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Non Operating Income high stood at $14.7 million for Q1 2022, and its period low was -$4.0 million during Q4 2021.
  • For the 3-year period, Supernus Pharmaceuticals' Non Operating Income averaged around $3.4 million, with its median value being $3.7 million (2024).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Non Operating Income tumbled by 138.49% in 2021 and then skyrocketed by 285.57% in 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Non Operating Income (Quarterly) stood at -$4.0 million in 2021, then soared by 159.30% to $2.4 million in 2022, then decreased by 17.25% to $2.0 million in 2023, then surged by 150.60% to $5.0 million in 2024, then slumped by 44.44% to $2.3 million in 2025.
  • Its Non Operating Income stands at $2.3 million for Q3 2025, versus $4.5 million for Q2 2025 and $4.4 million for Q1 2025.